4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
enGene Therapeutics Inc. (ENGN) operates in the Biotechnology industry and is headquartered in Montreal, Canada with about 81 employees. Its market capitalization is roughly $128 million. In the fiscal year ended 2025-10-31, ENGN reported $0M in revenue and ($117M) in net income.
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Interactive charts & full statements →
| Income statement | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($123M) | ($62M) | ($26M) | ($19M) | — |
| Net Income | ($117M) | ($55M) | ($100M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — | — |
| Operating Income (EBIT) | ($32M) | ($31M) | ($40M) | ($30M) | ($27M) | — | — |
| Net Income | ($30M) | ($30M) | ($38M) | ($29M) | ($26M) | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|
| Total Assets | $222M | $311M | $87M | $24M | — |
| Total Liabilities | $54M | $39M | $14M | $47M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ENGN viewer.
About TickerBase · Data methodology & sources